🏛️ Verified NIH Record • Updated 2025-09-29
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy (NCT04305613)
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy: A Prospective Longitudinal Cohort
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Abramson Cancer Center at Penn Medicine
🩺 Plain-English Summary (8th-Grade Level)
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
- Chemoradiation (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- University of Alabama — Birmingham, Alabama
- The Brigham and Women's Hospital — Boston, Massachusetts
- Washington University School of Medicine — St Louis, Missouri
- Rutger's University / Cancer Institute of New Jersey — New Brunswick, New Jersey
- Montefiore Medical Center — The Bronx, New York
- Lancaster General Hospital — Lancaster, Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania
- Chester County Hospital — West Chester, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiotoxicity
- Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) — Minneapolis, Minnesota
- S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity — Anchorage, Alaska
- Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure — San Diego, California
Explore by condition: All Cardiotoxicity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.